HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan
HDFC Asset Management Company Limited · Direct Plan · Growth
Fund overview
1% on or before 30D, Nil after 30D
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹1,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹1,000 | ₹1,273 | +273 |
| 3 Years | ₹1,000 | ₹2,063 | +1,063 |
| 5 Years | ₹1,000 | ₹3,342 | +2,342 |
Calculated using the fund's annualised return since inception (27.3% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
38 securitiesTop 10 holdings make up 45.6% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 9.39% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 8.28% |
| TREPS - Tri-party Repo | Cash/Deposits/Margins/Treps/Repo/Swaps | — | 4.67% |
| Alkem Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.64% |
| Cipla Ltd | Pharmaceuticals & Biotechnology | Large Cap | 4.15% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 3.69% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Large Cap | 3.65% |
| Max Healthcare Institute Ltd | Healthcare Services | Mid Cap | 3.61% |
| Aster Dm Healthcare Ltd | Healthcare Services | Mid Cap | 3.56% |
| Lupin Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.55% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹3,501 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹3,388 Cr
Exit load, stamp duty & tax
04-Oct-23
1% on or before 30D, Nil after 30D
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | -- |
| Beta | -- |
| Sharpe Ratio | -- |
| Sortino Ratio | -- |
| Treynor Ratio | -- |
| Jensen's Alpha | -- |
| Information Ratio | -- |
| R-Squared | -- |
| Max Drawdown | -- |
| Upside Capture | -- |
| Downside Capture | -- |
Fund management
Scheme Details
Investment objective
To Provide Long-Term Capital Appreciation By Investing Predominantly In Equity And Equity Related Securities Of Pharma And Healthcare Companies.
Fund house
HDFC Asset Management Company Limited
Frequently asked questions
What is the NAV of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?
The NAV of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is ₹20.82 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?
The expense ratio charged by HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is 1.03%.
What is the Min. SIP of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?
The minimum SIP investment in HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is ₹100 per month.
What is the Min. Lumpsum of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?
The minimum lumpsum investment in HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is ₹100.
What is the Exit Load of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?
The exit load for HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is: 1% on or before 30D, Nil after 30D
.svg){kind=small}